The estimated Net Worth of Paul J Isaac is at least $22.5 Million dollars as of 28 May 2024. Paul Isaac owns over 1,254 units of Stereotaxis stock worth over $6,034,388 and over the last 7 years Paul sold STXS stock worth over $16,424,933.
Paul has made over 50 trades of the Stereotaxis stock since 2019, according to the Form 4 filled with the SEC. Most recently Paul bought 1,254 units of STXS stock worth $2,358 on 28 May 2024.
The largest trade Paul's ever made was selling 2,000,000 units of Stereotaxis stock on 1 June 2021 worth over $14,500,000. On average, Paul trades about 56,327 units every 37 days since 2018. As of 28 May 2024 Paul still owns at least 2,768,068 units of Stereotaxis stock.
You can see the complete history of Paul Isaac stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is 530 5th Ave, New York, NY 10036, USA.
Over the last 6 years, insiders at Stereotaxis have traded over $16,447,723 worth of Stereotaxis stock and bought 502,585 units worth $872,120 . The most active insiders traders include Joe E Kiani, Paul J Isaac, and Myriam Curet. On average, Stereotaxis executives and independent directors trade stock every 39 days with the average trade being worth of $124,591. The most recent stock trade was executed by Paul J Isaac on 28 May 2024, trading 1,254 units of STXS stock currently worth $2,358.
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
Stereotaxis executives and other stock owners filed with the SEC include: